Treatment of epilepsy: Consensus of the Brazilian specialists;Tratamento de epilepsia: Consenso dos Especialistas Brasileiros

Arquivos de Neuro-Psiquiatria

Volumn 61, Issue 4, 2003, Pages 1045-1070

  Betting, Luiz Eduardo ^a   Kobayashi, Eliane ^a   Montenegro, Maria Augusta ^a   Min, Li Li ^a   Cendes, Fernando ^a   Guerreiro, Marilisa M ^a   Guerreiro, Carlos A M ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Antiepileptic drugs; Epilepsy; Seizures; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; ETHOSUXIMIDE; GABAPENTIN; LAMOTRIGINE; NITRAZEPAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; VIGABATRIN;

ABSENCE; ARTICLE; BRAZIL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION MAKING; EPILEPSY; GRAND MAL EPILEPSY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL EXPERT; MEDICAL SPECIALIST; META ANALYSIS; MULTICENTER STUDY; MYOCLONUS SEIZURE; PRACTICE GUIDELINE; PREVALENCE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SYNDROME DELINEATION; TREATMENT PLANNING; UNITED STATES;

EID: 0346888453     PISSN: 0004282X     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0004-282x2003000600032     Document Type: Article

References (58)

1. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-399.
2. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-319.
3. Goa KL, Ross SR, Chrisp P. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993;46:152-176.
4. Anhut H, Ashman P, Feuerstein TJ, Sauermann W, Saunders M, Schmidt B. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind placebo-controlled study. Epilepsia 1994;35:795-801.
5. U.S. Gabapentin Study Group. Gabapentin as add-on therapy in refractory epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology 1993;43:2292-2298.
6. Gram L. Oxcarbazepine. In Engel J Jr, Pedley TA (eds) Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven, 1997:1541-1546.
7. Kramer LD, Reife RA. Topiramate. In Engel J Jr, Pedley TA (eds) Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven, 1997:1593-1598.
8. Sachdeo RC, Leroy RF, Krauss GL, et al. Tiagabine therapy for complex partial seizures: a dose-frequency study. The Tiagabine Study Group. Arch Neurol 1997;54:595-601.
9. Theodore WH. Felbamate. In Engel J, Jr, Pedley TA (eds) Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven, 1997:1509-1514.
10. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik, I. Levetiracetam for partial seizures: results of a double-blind randomized clinical trial. Neurology 2000;55:236-242.
11. White HS. Comparative anticonvulsant and mechanistic pro-file of the established and newer antiepileptic drugs. Epilepsia 1999;40(Suppl 5):S2-10.
12. Wheless JW, Venkataraman V. New formations of drugs in epilepsy. Expert Opin Pharmacother 1999;1:49-160.
13. Wilder BJ. Vagal nerve stimulation. In Engel J Jr, Pedley TA (eds) Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven, 1997:1353-1358.
14. Vining EPG. Ketogenic diet. In Engel J Jr, Pedley TA (eds)Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven, 1997:1339-1344.
15. Wiebe S, Blume WT, Girvin JP, Eliaziw M. A randomized controlled trial of surgery for temporal lobe epilepsy. N Engl J Med 2001; 345:311-318.
16. Karceski S, Morrell M, Carpenter D. The expert consensus guidelines series: treatment of epilepsy. Epilepsy & Behavior 2001;2(Suppl 2):A1-A50.
17. Privitera MD. Evidence-based medicine and antiepileptic drugs. Epilepsia 1999;40(Suppl 5):S47-56.
18. Williamson PR, Marson AG, Tudur C, Hutton JL, Chadwick D. Individual patient data meta-analysis of randomized anti-epileptic drug monotherapy trials. J Eval Clin Pract 2000;6:205-214.
19. Kahn DA, Docherty JP, Carpenter D, Frances A. Consensus methods in practice guideline development: a review and description of a new method. Psychopharmacol Bull 1997;33:631-639.
20. Dalkey NC. The Delphi method: an experimental study of group opinion. Santa Monica, CA: Rand, 1969: Publication RM-58888 PR.
21. Woolfe SH. Practice guidelines, a new reality in medicine. Arch Intern Med 1992;152:946-952.
22. Brook RH, Chassin MR, Fink A, et al. A method for the detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care 1986;2:53-63.
23. Kahn DA, Carpenter D, Docherty JP, Frances A. The expert consensus guideline series: treatment of bipolar disorder. J Clin Psychiatry 1996;57(Suppl 12a):1-88.
24. Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP. The expert consensus guideline series: medication treatment of bipolar disorder 2000. Postgrad Med 2000;Apr:1-104.
25. McEvoy JP, Weiden PF, Smith TE, Carpenter D, Kahn DA, Frances A. The expert consensus guideline series: treatment of schizophrenia. J Clin Psychiatry 1996;57(suppl 12b):1-58.
26. McEvoy JP, Schiefler PL, Frances A. The expert consensus guideline series: treatment of schizophrenia 1999. J Clin Psychiatry 1999; 60(Suppl 11):1-80.
27. March JS, Frances A, Kahn DA, Carpenter D. The expert consensus guideline series: treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997;58(Suppl 4):1-72.
28. Alexopoulos GS, Silver JM, Kahn DA, Frances A, Carpenter D. The expert consensus guideline series: treatment of agitation in older persons with dementia. Postgrad Med Spec Rep 1998;Apr:1-88.
29. Foa EB, Davidson JRT, Frances A. The expert consensus guideline series: treatment of posttraumatic stress disorder. J Clin Psychiatry 1999;60(Suppl 16):1-76.
30. Rush AJ, Frances A. Expert consensus guideline series: treatment of psychiatric and behavioral problems in mental retardation. Am J Ment Retard 2000;105:159-228.
31. Conners CK, March JS, Frances A, Wells KC, Ross R. Expert consensus guideline series: treatment of attention-deficit/hyperactivity disorder. Attention Disord 2001;4(Suppl 1):S1-128.
32. Altschuler LL, Cohen LS, Moline ML, Kahn DA, Carpenter D, Docherty JP. The expert consensus guideline series: treatment of depression in women 2001. Postgrad Med Spec Rep 2001;March:1-115.
33. Allen MH, Currier GW, Hughes DH, Reyes-Harde M, Docherty JP. The expert consensus guideline series: treatment of behavioral emergencies. Postgrad Med Spec Rep 2001;May:1-88.
34. Alexopoulos GS, Katz IR, Reynolds CF, III, Carpenter D, Docherty JP. The expert consensus guideline series: pharmacotherapy of depressive disorders in older patients. Postgrad Med Spec Rep 2001;Oct:1-88.
35. Stefan H, Snead CO. Absence seizures. In Engel J Jr, Pedley TA (eds) Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven, 1997:579-590.
36. Wallace SJ. Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine, and zonisamide. Epilepsy Res 1998;29:147-154.
37. Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998;39:508-512.
38. Mattson RH. Comparison of valproate and carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992;327:765-771.
39. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 985; 313:145-151.
40. Deckers CL, Czuczwar SJ, Hekster YA, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 2000;41:1364-1374.
41. Schmidt D. Modern management of epilepsy: rational polytherapy. Baillieres Clin Neurol 1996;5:757-763.
42. Montenegro MAS, Cendes F, Noronha ALA, Mory SB, Carvalho MI, Marques LHN, Guerreiro CAM. Efficacy of clobazam as add-on therapy in patients with refractory partial epilepsy. Epilepsia 2001;42:539-542.
43. Satishchandra P, Varadarajalu R, Rajaram P.Long-term use of clobazam in the management of intractable epilepsy: a prospective study. Neurology (India) 1998;46:284-287.
44. Genton P, Bauer J, Duncan S, et al. On the association between valproate and polycystic ovary syndrome. Epilepsia 2001;42:295-394.
45. Morrell MJ. Effects of epilepsy on women's reproductive health. Epilepsia 1998;39(Suppl 8):S32-37.
46. Isojarvi JI, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KT, Myllyla VV. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579-584.
47. Isojarvi JI, Rattya J, Myllyla VV, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998;43:446-451.
48. Sirven JI. Acute and chronic seizures in patients older than 60 years. Mayo Clin Proc 2001;76:175-183.
49. Willmore LJ. Choice of newer anticonvulsant drugs in older patients. Drugs Aging 2000;17:441-452.
50. Ramsay RE, Pryor F. Epilepsy in the elderly. Neurology 2000; 55(Suppl 1):S9-14.
51. Meador KJ. Current discoveries on the cognitive effects of antiepileptic drugs. Pharmacotherapy 2000;20S:185-190.
52. Dam M, Ekberg E, Loyning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989;3:70-76.
53. Trimble MR. Neuropsychiatric consequences of pharmacotherapy. In Engel J Jr, Pedley TA (eds). Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven, 1997:2161-2170.
54. Frances AJ, Kahn DA, Carpenter D, Docherty JP, Donovan SL. The expert consensus guidelines for treating depression in bipolar disorder. J Clin Psychiatry 1998;59(Suppl 4):73-79.
55. Keck P, McElroy SL, Arnold LM. Bipolar disorder. Med Clin N Am 2001;85:645-661.
56. Kwan P, Brodie MJ. Neuropsychological effects of epilepsy and antiepileptic drugs. Lancet 2001;357:216-222.
57. Perucca E. Drug Treatment. In Shorvon S, Dreifuss F, Fish D, Thomas D (eds). The treatment of epilepsy. London Blackwell: 1996:152-168.
58. Meinardi H. Why phenobarbital? Epicaded News 1993;1:7-8.